Published in N Engl J Med on July 07, 1977
Ten year survival after heart transplantation: palliative procedure or successful long term treatment? Heart (1999) 1.43
Effects of captopril in acute and chronic heart failure. Correlations with plasma levels of noradrenaline, renin, and aldosterone. Br Heart J (1983) 1.15
The Tromsø study: physical fitness, self reported physical activity, and their relationship to other coronary risk factors. J Epidemiol Community Health (1992) 1.14
Cardiac alpha1-adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance. Pharmacol Rev (2013) 0.96
Felodipine in patients with chronic heart failure: discrepant haemodynamic and clinical effects. Br Heart J (1987) 0.93
Afterload reduction: a comparison of captopril and nifedipine in dilated cardiomyopathy. Br Heart J (1986) 0.92
Efficacy of felodipine in chronic congestive heart failure: a placebo controlled haemodynamic study at rest and during exercise and orthostatic stress. Br Heart J (1987) 0.90
Factors influencing survival and mode of death in severe chronic ischaemic cardiac failure. Br Heart J (1987) 0.90
Vasodilators in heart failure. Br Med J (Clin Res Ed) (1982) 0.87
A randomized pilot study of aortic waveform guided therapy in chronic heart failure. J Am Heart Assoc (2014) 0.86
Acute haemodynamic effects of oral prazosin in severe mitral regurgitation. Br Heart J (1980) 0.82
Acute haemodynamic comparison of amrinone and pirbuterol in chronic heart failure. Additional effects of isosorbide dinitrate. Br Heart J (1983) 0.79
A review of the haemodynamic effects of labetalol in man. Br J Clin Pharmacol (1982) 0.79
Arterial mechanical properties in dilated cardiomyopathy. Aging and the response to nitroprusside. J Clin Invest (1991) 0.78
Effect of prostacyclin on vascular capacity in the dog. J Clin Invest (1985) 0.78
Afterload reduction treatment for large ventricular septal defects. Dependence of haemodynamic effects of hydralazine on pretreatment systemic blood flow. Br Heart J (1983) 0.77
Left ventricular wall stress distribution in chronic pressure and volume overload: effect of normal and depressed contractility on regional stress-velocity relations. Basic Res Cardiol (1990) 0.77
Contributions of hemodynamic monitoring to the treatment of chronic congestive heart failure. Can Med Assoc J (1979) 0.75
Physiologic significance of hemodynamic measurements and their derived indices. Can Med Assoc J (1979) 0.75
Vasodilator treatment with isosorbide dinitrate and hydralazine in chronic heart failure. Br Heart J (1981) 0.75
Clinical and haemodynamic effects of low dose captopril in severe chronic heart failure. Br J Clin Pharmacol (1982) 0.75
A physarum-inspired prize-collecting steiner tree approach to identify subnetworks for drug repositioning. BMC Syst Biol (2016) 0.75
Current concepts in vasodilator therapy for advanced or refractory congestive heart failure. Can Vet J (1988) 0.75
Anesthetic management of descending thoracic aortobifemoral bypass for aortoiliac occlusive disease: Our experience. Saudi J Anaesth (2014) 0.75
Oral OPC-8212 for the treatment of congestive heart failure: hemodynamic improvement and increased exercise capacity. Heart Vessels (1986) 0.75
Anaesthetic problems in cross clamping of the thoracic aorta. Ann R Coll Surg Engl (1988) 0.75
Depressed Exercise Peak Ejection Rate Detected on Ambulatory Radionuclide Monitoring Reflects End-Stage Cardiac Inotropic Reserve and Predicts Mortality in Ischaemic Cardiomyopathy. Cardiol Res (2012) 0.75
Vasodilators in heart failure. Conclusions from V-HeFT II and rationale for V-HeFT III. Drugs (1994) 0.75
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med (1996) 12.77
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med (1992) 8.38
Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med (1984) 6.74
Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med (1986) 6.58
Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med (2001) 5.30
Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med (2001) 3.44
Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation (1996) 3.14
Modern strategies to prevent coronary sequelae and stroke in hypertensive patients differ from the JNC V Consensus Guidelines. Am J Hypertens (1994) 2.91
Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. Am J Cardiol (1981) 2.74
Right ventricular infarction. Clinical and hemodynamic features. Am J Cardiol (1974) 2.30
Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol (1983) 2.24
Improved left ventricular function during nitroprusside infusion in acute myocardial infarction. Lancet (1972) 2.24
Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med (1985) 2.22
Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol (1993) 2.15
Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail (1999) 1.96
Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol (1982) 1.91
Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure. Circulation (1980) 1.88
Age-related abnormalities in arterial compliance identified by pressure pulse contour analysis: aging and arterial compliance. Hypertension (1999) 1.86
Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol (1983) 1.80
Treatment of refractory heart failure with infusion of nitroprusside. N Engl J Med (1974) 1.78
Vasodilator therapy for heart failure. The influence of impedance on left ventricular performance. Circulation (1973) 1.78
Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation (1978) 1.77
Relation of right ventricular ejection fraction to exercise capacity in chronic left ventricular failure. Am J Cardiol (1984) 1.72
Relation between hemodynamic and ventilatory responses in determining exercise capacity in severe congestive heart failure. Am J Cardiol (1984) 1.71
Functional capacity of patients with chronic left ventricular failure. Relationship of bicycle exercise performance to clinical and hemodynamic characterization. Am J Med (1979) 1.71
Systemic and renal hemodynamics in oliguric hepatic failure: effect of volume expansion. J Clin Invest (1967) 1.67
The neurohumoral axis in congestive heart failure. Ann Intern Med (1984) 1.66
Rapid, accurate and simultaneous noninvasive assessment of right and left ventricular mass with nuclear magnetic resonance imaging using the snapshot gradient method. J Am Coll Cardiol (1992) 1.64
Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J (1998) 1.59
Relationship of exercise capacity to resting left ventricular performance and basal plasma norepinephrine levels in patients with congestive heart failure. Am Heart J (1982) 1.57
Vasodilator therapy of cardiac failure (second of two parts). N Engl J Med (1977) 1.50
Neurohumoral control mechanisms in congestive heart failure. Am Heart J (1981) 1.47
Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation (1993) 1.42
Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation (1993) 1.41
Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placebo. Am Heart J (1982) 1.39
The fallacy of the mean. J Card Fail (2001) 1.39
First- and third-order models for determining arterial compliance. J Hypertens Suppl (1992) 1.38
Nitrate therapy for congestive heart failure. JAMA (1978) 1.37
Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure. Am J Med (1980) 1.37
Vascular compliance and cardiovascular disease: a risk factor or a marker? Am J Hypertens (1997) 1.34
Sustained hemodynamic effects without tolerance during long-term isosorbide dinitrate treatment of chronic left ventricular failure. Am J Cardiol (1980) 1.29
Exercise testing in chronic congestive heart failure. Am J Cardiol (1984) 1.29
Regional differences in adrenergic function within the left ventricle. Am J Physiol (1984) 1.28
Effect of isosorbide dinitrate on response to submaximal and maximal exercise in patients with congestive heart failure. Am J Cardiol (1979) 1.27
Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition. Circulation (1995) 1.26
Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects. Circulation (1977) 1.24
Quantitation of portasystemic shunting from the splenic and mesenteric beds in alcoholic liver disease. Am J Med (1972) 1.22
Response of plasma norepinephrine and epinephrine to dynamic exercise in patients with congestive heart failure. Am J Cardiol (1982) 1.20
Relationship between C-reactive protein and arterial stiffness in an asymptomatic population. J Hum Hypertens (2005) 1.19
Hemodynamic improvement after oral hydralazine in left ventricular failure: a comparison with nitroprusside infusion in 16 patients. Ann Intern Med (1977) 1.19
Pulmonary versus systemic hemodynamics in determining exercise capacity of patients with chronic left ventricular failure. Am Heart J (1985) 1.18
Hemodynamic effects of orally administered isosorbide dinitrate in patients with congestive heart failure. Circulation (1974) 1.17
The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation (1993) 1.16
Right ventricular infarction revisited. Am J Cardiol (1979) 1.15
Effectiveness of long-term vasodilator administration in the treatment of chronic left ventricular failure. Prog Cardiovasc Dis (1982) 1.15
Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation (1993) 1.14
Hemodynamic effect of dobutamine in patients with severe heart failure. Am J Cardiol (1975) 1.14
Epidemiologic patterns, clinical evaluation, and long-term prognosis in chronic congestive heart failure. Am J Med (1986) 1.14
Comparative hemodynamic effects of chewable isosorbide dinitrate and nitroglycerin in patients with congestive heart failure. Circulation (1975) 1.14
Cardiac and peripheral vascular effects of digitalis in clinical cardiogenic shock. Am Heart J (1969) 1.13
Serial serum creatine phosphokinase MB isoenzyme activity after myocardial infarction. Studies in the baboon and man. Circulation (1977) 1.11
Hemodynamic effects of vasodilators and long-term response in heart failure. J Am Coll Cardiol (1984) 1.11
Vascular abnormalities associated with long-term cigarette smoking identified by arterial waveform analysis. Am J Med (1997) 1.10
Hypertension--1974. Arch Intern Med (1974) 1.09
Relationship of plasma volume changes to resistance and capacitance vessel effects of sympathomimetic amines and angiotensin in man. Clin Sci (1966) 1.09
Effects of enalapril, a new angiotensin-converting enzyme inhibitor, in a controlled trial in heart failure. J Am Coll Cardiol (1985) 1.09
Blood pressure and cardiac performance. Am J Med (1973) 1.09
Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure. Veterans Affairs cooperative studies V-HeFT I and II. V-HeFT VA Cooperative Studies Group. Circulation (1993) 1.08
The prevention of heart failure--a new agenda. N Engl J Med (1992) 1.07
Improving outcomes in heart failure. Eur Heart J (1998) 1.07
Central venous pressure as a guide to volume expansion. Ann Intern Med (1967) 1.06
Hyponatraemia as a marker for high renin heart failure. Br Heart J (1982) 1.06
Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation (1993) 1.04
Comparative hemodynamic effects of inotropic and vasodilator drugs in severe heart failure. Circulation (1977) 1.03
Comparative hemodynamic effects of converting enzyme inhibitor and sodium nitroprusside in severe heart failure. Am J Cardiol (1980) 1.03
Heart failure: mechanisms of cardiac and vascular dysfunction and the rationale for pharmacologic intervention. FASEB J (1990) 1.03
Acquired coronary artery fistula to the left ventricle after acute myocardial infarction. Am J Cardiol (1986) 1.03
Hemodynamic and clinical response to enalapril, a long-acting converting-enzyme inhibitor, in patients with congestive heart failure. Circulation (1984) 1.03
The effectiveness of cardiology consultation. Concordance with diagnostic and drug recommendations. Chest (1981) 1.03
Fish oil improves arterial compliance in non-insulin-dependent diabetes mellitus. Arterioscler Thromb (1994) 1.01
Clinical application of a simple, specific bioassay technique for measuring renin activity. Am J Med Sci (1969) 1.01
Bedside catheterization of the left ventricle. Am J Cardiol (1970) 1.01